FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection

benzinga.com/news/fda/25/06/45890526/fda-expands-abbvies-mavyret-label-to-include-pediatric-patients-with-hepatitis-c-infection

The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc’s (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy.
It is now approved for adults and pediatric patients three years and older with acute or…

This story appeared on benzinga.com, 2025-06-11 17:46:36.
The Entire Business World on a Single Page. Free to Use →